New DGRec Tool Enables Programmable Rapid Evolution of Proteins in Bacteria
Scientists harness natural bacterial mutation systems to engineer proteins at unprecedented speed, opening doors for drug and therapy development.
Summary
Researchers at Institut Pasteur and UCSF have developed DGRec, a new genetic engineering tool that uses naturally occurring bacterial systems called diversity-generating retroelements to rapidly mutate and evolve specific protein sequences on demand. By coupling these elements with a technique called recombineering, the team can target precise DNA windows of 50 to 200 base pairs and introduce up to 24 mutations within 48 hours. The system was successfully applied to engineer bacteriophage host range, evolve modified CRISPR proteins, and accelerate the development of nanobodies — small antibody fragments with therapeutic potential. The researchers also demonstrated the approach works in yeast, suggesting broader applicability. This platform could dramatically accelerate the development of new biologics, gene editing tools, and targeted therapies.
Detailed Summary
Protein engineering is central to modern medicine, but evolving proteins with desired properties typically requires slow, labor-intensive screening processes. A new tool called DGRec, developed by an international team at Institut Pasteur and UCSF, could change that by harnessing the natural mutation machinery of bacteria to rapidly diversify proteins on demand.
Diversity-generating retroelements (DGRs) are natural bacterial systems that use an error-prone reverse transcriptase to introduce targeted mutations, accelerating the evolution of specific proteins. The researchers coupled DGRs with recombineering — a technique for inserting DNA sequences into bacterial chromosomes — to create a programmable platform for directed evolution in Escherichia coli.
The system achieved mutation rates as high as 1.38 × 10⁻² per base per generation, allowing up to 24 mutations to accumulate in a single target sequence within 48 hours. Crucially, the reverse transcriptase's bias toward mutating adenine residues helps maximize sequence diversity while minimizing nonsense mutations that would destroy protein function — an elegant natural safeguard.
The team validated DGRec across three applications: engineering bacteriophage λ to infect new bacterial hosts, evolving variants of dCas9 (a CRISPR tool), and accelerating nanobody evolution using a bacterial display system. They also demonstrated DGR-mediated mutagenesis in yeast, expanding the platform's potential reach beyond bacteria.
For longevity and regenerative medicine, the implications are significant. Nanobodies and engineered CRISPR tools are increasingly explored as therapeutic agents for cancer, autoimmune disease, and age-related conditions. A faster, more programmable evolution platform could compress the timeline from target identification to clinical candidate. Caveats include that this summary is based on the abstract only, and real-world translation to mammalian therapeutic development will require additional validation steps.
Key Findings
- DGRec achieves mutation rates up to 1.38 × 10⁻² per base per generation, enabling 24 mutations in 48 hours.
- The system targets user-defined DNA windows of 50–200 bp with high precision and minimal nonsense mutations.
- DGRec successfully evolved nanobodies, dCas9 variants, and phage host-range proteins in bacteria.
- DGR-mediated mutagenesis was demonstrated in yeast, suggesting applicability beyond bacterial systems.
- Natural adenine-biased mutation of the reverse transcriptase maximizes sequence diversity while preserving protein function.
Methodology
The study developed DGRec by coupling diversity-generating retroelements with recombineering in E. coli, enabling programmable targeted hypermutation of defined sequence windows. Researchers characterized reverse transcriptase sequence biases and validated the platform across multiple protein engineering applications including phage engineering, CRISPR variant evolution, and nanobody development. Feasibility in yeast was also demonstrated using an adapted recombination and selection strategy.
Study Limitations
This summary is based on the abstract only, as the full paper is not open access, limiting assessment of experimental detail and statistical rigor. The platform has been demonstrated in bacteria and yeast but not yet in mammalian cells, which are more directly relevant to human therapeutic development. Patent applications have been filed by the authors, indicating potential commercial interests that may influence future access and development.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.